Form 424B4 - Prospectus [Rule 424(b)(4)]:
SEC Accession No. 0001213900-14-005747
Filing Date
2014-08-14
Accepted
2014-08-13 18:05:14
Documents
16

Document Format Files

Seq Description Document Type Size
1 PROSPECTUS f424b40814_dandrit.htm 424B4 2438248
2 img001_v1.jpg GRAPHIC 4919
3 sunrise.jpg GRAPHIC 10685
4 img002_v1.jpg GRAPHIC 6426
5 img003_v1.jpg GRAPHIC 29567
6 img004_v1.jpg GRAPHIC 28027
7 img012.jpg GRAPHIC 34408
8 img005_v1.jpg GRAPHIC 7409
9 img006_v1.jpg GRAPHIC 33049
10 img007_v1.jpg GRAPHIC 50321
11 img008_v1.jpg GRAPHIC 55507
12 img008a_v1.jpg GRAPHIC 15416
13 img009_v1.jpg GRAPHIC 6099
14 img.jpg GRAPHIC 27816
15 img010_v1.jpg GRAPHIC 13917
16 benchmark.jpg GRAPHIC 9058
  Complete submission text file 0001213900-14-005747.txt   2899438
Mailing Address DANDRIT BIOTECH A/S FRUEBJERGVEJ 3 BOX 62 2100 COPENHAGEN G7
Business Address DANDRIT BIOTECH A/S FRUEBJERGVEJ 3 BOX 62 2100 COPENHAGEN G7 45 39179840
DanDrit Biotech USA, Inc. (Filer) CIK: 0001527728 (see all company filings)

EIN.: 452259340 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B4 | Act: 33 | File No.: 333-193965 | Film No.: 141038813
SIC: 2834 Pharmaceutical Preparations